References
- Kirsch R, Pentecost M, Hall P, et al. Role of colonoscopic biopsy in distinguishing between Crohn’s disease and intestinal tuberculosis. J Clin Pathol. 2006;59:840–844.
- Epstein D, Watermeyer G, Kirsch R. The diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373–1388.
- Pulimood AB, Amarapurkar DN, Ghoshal U, et al. Differentiation of Crohn's disease from intestinal tuberculosis in India in 2010. World J Gastroenterol. 2011;17:433–443.
- Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–736.
- Das B, Kashino SS, Pulu I, et al. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Transl Med. 2013;30:5.
- Raghuvanshi S, Sharma P, Singh S, et al. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci USA. 2010;107:21653–21658.
- Banerjee R, Balaji M, Sasikala M, et al. Granulomas of intestinal tuberculosis and Crohn’s disease can be differentiated by CD73cell surface marker expression: a pilot study. Dig Dis Sci. 2013;58:2301–2307.
- Gomollón F, Dignass A, Annes V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. ECCOJC. 2017;11:3–25.
- Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med. 2012;367:2322–2333.
- Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol. 2014;5:304.
- Colgan SP, Eltzschig HK, Eckle T, et al. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal. 2006;2:351–360.
- Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499–3506.
- Kusner DJ, Barton JA. ATP stimulates human macrophages to kill intracellular virulent Mycobacterium tuberculosis via calcium-dependent phagosome-lysosome fusion. J. Immunol. 2001;167:3308–3315.
- Petit-Jentreau L, Jouvion G, Charles P, et al. Ecto-5=-nucleotidase (CD73) deficiency in Mycobacterium tuberculosis infected mice enhances neutrophil recruitment. Infect Immun. 2015;83:3666–3674.
- Bynoe MS, Waickman AT, Mahamed DA, et al. CD73 is critical for the resolution of murine colonic inflammation. J Biomed Biotechnol. 2012;2012:260983.
- Louis NA, Robinson AM, MacManus CF, et al. Control of IFN-alphaA by CD73: implications for mucosal inflammation. J Immunol. 2008;180:4246–4255.
- Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NF kappa B. Proc Natl Acad Sci USA. 1999;96:6377–6381.
- Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998;101:295–300.
- Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 2010;59:1662–1669.
- Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64–71.
- Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells. 2013;31:2575–2581.
- Panes J, Garcia-Olmo D, Van Assche G, et al. Expanded allogeneic adipose derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281–1290.